So what if numbers dont jive and sales are off, Tesla makes the best car. Its the only car company with Elon.
They're not knockoffs, Chinese actually are able to design a mask, etc.
China manufacturers are entering a lot of non-traditional areas such as medical devices, aircraft, etc.
They've been there for awhile.
You bought above the high of the day in after hours, and you think thats good?
Sooner or later people might realize there's only so much money to be had in the Ebola arena, and there's a lot of players.
SPEX is getting close to hitting on one or more. They've got nine actions going now? Patience is all it takes.
Joining the party for investigations / lawsuits today:
Glancy Binkow and Goldberg
Block & Leviton
Gewitz and Grossman
Johnson and Weaver LLP
The Rosen Law Firm
How many more by end of next week?
Even SRPT stays in the news with their product, saying that even though they suspended work on it, they still have dozens of doses available.
(CNN) -- A highly anticipated test of an experimental Ebola vaccine will begin next week at the National Institutes of Health, amid mounting anxiety about the spread of the deadly virus in West Africa.
After an expedited review by the U.S. Food and Drug Administration, researchers were given the green light to begin what's called a human safety trial, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.
It will be the first test of this type of Ebola vaccine in humans.
The experimental vaccine, developed by the pharmaceutical company GlaxoSmithKline and the NIAID, will first be given to three healthy human volunteers to see if they suffer any adverse effects. If deemed safe, it will then be given to another small group of volunteers, aged 18 to 50, to see if it produces a strong immune response to the virus. All will be monitored closely for side effects.
... Funding from an international consortium formed to fight Ebola will enable GlaxoSmithKline to begin manufacturing up to 10,000 additional doses of the vaccine while clinical trials are ongoing, the pharmaceutical company said in a statement. These doses would be made available if the World Health Organization decides to allow emergency immunizations in high-risk communities.
The GSK/NIAID vaccine is one of two leading candidate vaccines. The other was developed by the Public Health Agency of Canada and licensed this month to NewLink Genetics, a company based in Iowa.
According to the NIH, safety trials of that vaccine will start this fall.
BioCryst Pharmaceuticals, Inc. announced this morning that their small-molecule, nucleoside analogue, BCX-4430, would be entering a dose ranging efficacy study in non-human primates within the next few weeks.
This study could potentially meet all of the criteria for FDA’s Animal Rule, a path by which drugs tested in animals could move to emergency treatment of humans while human safety trials proceed concomitantly.
The Nature paper demonstrated that BCX-4430 given after a viral challenge could stop Ebola and related Marburg infections from taking hold in rodents. Most notably, BCX-4430 given 48 hours after Marburg virus infection confers complete protection to cynmologous monkeys.
So, unlike with a vaccine, BCX-4430 is being developed as a post-exposure measure for hose in environments where conditions are conducive to accidental viral exposure.
Much of the press regarding Ebola treatment has focused on passive immunotherapy agents, such as Mapp Biopharmaceutical’s ZMapp, vaccines from private and public entities, and small RNA drugs from companies such as Tekmira and Sarepta.
Biocryst’s BCX-4430 is a much smaller molecule intended for broad spectrum anti-viral use, described by the company as “an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.”
Not really. If people were interested they would help fund infrastructure in Africa which would preclude these outbreaks.